Effective Triple-Negative Breast Cancer Targeted Treatment Using iRGD-Modified RBC Membrane-Camouflaged Nanoparticles

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Sohn J, Liu S, Parinyanitikul N, et al. cMET activation and EGFR-directed therapy resistance in triple-negative breast cancer. J Cancer. 2014;5(9):745–753. doi:10.7150/jca.9696
   PubMed Web of Science ®Google Scholar
• Waks AG, Winer EP. Breast cancer treatment. JAMA. 2019;321(3):316. doi:10.1001/jama.2018.20751
   PubMed Web of Science ®Google Scholar
• Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397(10286):1750–1769. doi:10.1016/S0140-6736(20)32381-3
   PubMed Web of Science ®Google Scholar
• Li N, Deng Y, Zhou L, et al. Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: results from the Global Burden of Disease Study 2017. J Hematol Oncol. 2019;12(1):140. doi:10.1186/s13045-019-0828-0
   PubMed Web of Science ®Google Scholar
• Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for Treatment. Cancer Discov. 2019;9(2):176–198. doi:10.1158/2159-8290.CD-18-1177
   PubMed Web of Science ®Google Scholar
• Pusztai L, Foldi J, Dhawan A, DiGiovanna MP, Mamounas EP. Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers. Lancet Oncol. 2019;20(7):e390–e396. doi:10.1016/S1470-2045(19)30158-5
   PubMedGoogle Scholar
• Borri F, Granaglia A. Pathology of triple negative breast cancer. Semin Cancer Biol. 2020;72:136–145.
   PubMedGoogle Scholar
• Hwang SY, Park S, Kwon Y. Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacol Ther. 2019;199:30–57.
   PubMed Web of Science ®Google Scholar
• Franzoi MA, Romano E, Piccart M. Immunotherapy for early breast cancer: too soon, too superficial, or just right? Ann Oncol. 2021;32(3):323–336. doi:10.1016/j.annonc.2020.11.022
   PubMed Web of Science ®Google Scholar
• Ruoslahti E. Tumor penetrating peptides for improved drug delivery. Adv Drug Deliv Rev. 2017;110–111:3–12. doi:10.1016/j.addr.2016.03.008
   PubMed Web of Science ®Google Scholar
• Wang Y, Xie Y, Kilchrist KV, Li J, Duvall CL, Oupický D. Endosomolytic and tumor-penetrating mesoporous silica nanoparticles for siRNA/miRNA combination cancer therapy. ACS Appl Mater Interfaces. 2020;12(4):4308–4322. doi:10.1021/acsami.9b21214
   PubMed Web of Science ®Google Scholar
• Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci U S A. 2009;106(38):16157–16162. doi:10.1073/pnas.0908201106
   PubMed Web of Science ®Google Scholar
• Kim D, Kang J, Wang T, et al. Two-photon in vivo imaging with porous silicon nanoparticles. Adv Mater. 2017;29:39. doi:10.1002/adma.201703309
   Google Scholar
• Ding N, Zou Z, Sha H, et al. iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer. Nat Commun. 2019;10(1):1336. doi:10.1038/s41467-019-09296-6
   PubMed Web of Science ®Google Scholar
• Zuo H. iRGD: a promising peptide for cancer imaging and a potential therapeutic agent for various cancers. J Oncol. 2019;2019:9367845. doi:10.1155/2019/9367845
   PubMed Web of Science ®Google Scholar
• Fu S, Xu X, Ma Y, Zhang S, Zhang S. RGD peptide-based non-viral gene delivery vectors targeting integrin α(v)β(3) for cancer therapy. J Drug Target. 2019;27(1):1–11. doi:10.1080/1061186X.2018.1455841
   PubMed Web of Science ®Google Scholar
• Li M, Tang Z, Zhang D, et al. Doxorubicin-loaded polysaccharide nanoparticles suppress the growth of murine colorectal carcinoma and inhibit the metastasis of murine mammary carcinoma in rodent models. Biomaterials. 2015;51:161–172. doi:10.1016/j.biomaterials.2015.02.002
   PubMed Web of Science ®Google Scholar
• Alipour M, Baneshi M, Hosseinkhani S, et al. Recent progress in biomedical applications of RGD-based ligand: from precise cancer theranostics to biomaterial engineering: a systematic review. J Biomed Mater Res A. 2020;108(4):839–850. doi:10.1002/jbm.a.36862
   PubMed Web of Science ®Google Scholar
• Hurtado de Mendoza T, Mose ES, Botta GP, et al. Tumor-penetrating therapy for beta5 integrin-rich pancreas cancer. Nat Commun. 2021;12(1):1541. doi:10.1038/s41467-021-21858-1
   PubMedGoogle Scholar
• Sun Q, Zhou Z, Qiu N, Shen Y. Rational design of cancer nanomedicine: nanoproperty integration and synchronization. Adv Mater. 2017;29:14. doi:10.1002/adma.201606628
   Google Scholar
• Kong L, Campbell F, Kros A. DePEGylation strategies to increase cancer nanomedicine efficacy. Nanoscale Horizons. 2019;4(2):378–387. doi:10.1039/C8NH00417J
   PubMed Web of Science ®Google Scholar
• Dai J, Dong X, Wang Q, Lou X, Xia F, Wang S. PEG-polymer encapsulated aggregation-induced emission nanoparticles for tumor theranostics. Adv Healthc Mater. 2021;e2101036. doi:10.1002/adhm.202101036
   PubMedGoogle Scholar
• Ishida T, Ichihara M, Wang X, et al. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release. 2006;112(1):15–25. doi:10.1016/j.jconrel.2006.01.005
   PubMed Web of Science ®Google Scholar
• Zou Y, Liu Y, Yang Z, et al. Effective and targeted human orthotopic glioblastoma xenograft therapy via a multifunctional biomimetic nanomedicine. Adv Mater. 2018;30(51):e1803717. doi:10.1002/adma.201803717
   PubMed Web of Science ®Google Scholar
• Castro F, Martins C, Silveira MJ, Moura RP, Pereira CL, Sarmento B. Advances on erythrocyte-mimicking nanovehicles to overcome barriers in biological microenvironments. Adv Drug Deliv Rev. 2021;170:312–339. doi:10.1016/j.addr.2020.09.001
   PubMed Web of Science ®Google Scholar
• Izzati Mat Rani NN, Alzubaidi ZM, Azhari H. Novel engineering: biomimicking erythrocyte as a revolutionary platform for drugs and vaccines delivery. Eur J Pharmacol. 2021;900:174009. doi:10.1016/j.ejphar.2021.174009
   PubMedGoogle Scholar
• Xia Q, Zhang Y, Li Z, Hou X, Feng N. Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application. Acta pharmaceutica Sinica B. 2019;9(4):675–689. doi:10.1016/j.apsb.2019.01.011
   PubMed Web of Science ®Google Scholar
• Yang Z, Gao D, Guo X, et al. Fighting immune cold and reprogramming immunosuppressive tumor microenvironment with red blood cell membrane-camouflaged nanobullets. ACS Nano. 2020;14(12):17442–17457. doi:10.1021/acsnano.0c07721
   PubMed Web of Science ®Google Scholar
• Li S, Liu J, Sun M, Wang J, Wang C, Sun Y. Cell membrane-camouflaged nanocarriers for cancer diagnostic and therapeutic. Front Pharmacol. 2020;11:24. doi:10.3389/fphar.2020.00024
   PubMedGoogle Scholar
• Jo S, Kim I, Lee W, et al. Highly sensitive and wide-range nanoplasmonic detection of fibrinogen using erythrocyte membrane-blanketed nanoparticles. Biosens Bioelectron. 2019;135:216–223. doi:10.1016/j.bios.2019.04.030
   PubMedGoogle Scholar
• Xie W, Deng WW, Zan M, et al. Cancer cell membrane camouflaged nanoparticles to realize starvation therapy together with checkpoint blockades for enhancing cancer therapy. ACS Nano. 2019;13(3):2849–2857. doi:10.1021/acsnano.8b03788
   PubMed Web of Science ®Google Scholar
• Que X, Su J, Guo P, et al. Study on preparation, characterization and multidrug resistance reversal of red blood cell membrane-camouflaged tetrandrine-loaded PLGA nanoparticles. Drug Deliv. 2019;26(1):199–207. doi:10.1080/10717544.2019.1573861
   PubMed Web of Science ®Google Scholar
• Xie X, Hu X, Li Q, et al. Unraveling cell-type-specific targeted delivery of membrane-camouflaged nanoparticles with plasmonic imaging. Nano Lett. 2020;20(7):5228–5235. doi:10.1021/acs.nanolett.0c01503
   PubMedGoogle Scholar
• Nguyen TL, Choi Y, Kim J. Mesoporous silica as a versatile platform for cancer immunotherapy. Adv Mater. 2019;31(34):e1803953. doi:10.1002/adma.201803953
   PubMed Web of Science ®Google Scholar
• Nie D, Dai Z, Li J, et al. Cancer-cell-membrane-coated nanoparticles with a yolk-shell structure augment cancer chemotherapy. Nano Lett. 2020;20(2):936–946. doi:10.1021/acs.nanolett.9b03817
   PubMed Web of Science ®Google Scholar
• Jiang Q, Liu Y, Guo R, et al. Erythrocyte-cancer hybrid membrane-camouflaged melanin nanoparticles for enhancing photothermal therapy efficacy in tumors. Biomaterials. 2019;192:292–308. doi:10.1016/j.biomaterials.2018.11.021
   PubMed Web of Science ®Google Scholar
• Dehaini D, Wei X, Fang RH, et al. Erythrocyte-platelet hybrid membrane coating for enhanced nanoparticle functionalization. Adv Mater. 2017;29(16):1606209.
   Web of Science ®Google Scholar
• Mao X, Liu J, Gong Z, et al. iRGD-conjugated DSPE-PEG2000 nanomicelles for targeted delivery of salinomycin for treatment of both liver cancer cells and cancer stem cells. Nanomedicine. 2015;10(17):2677–2695. doi:10.2217/nnm.15.106
   PubMed Web of Science ®Google Scholar
• Zhang B, Luo Z, Liu J, Ding X, Li J, Cai K. Cytochrome c end-capped mesoporous silica nanoparticles as redox-responsive drug delivery vehicles for liver tumor-targeted triplex therapy in vitro and in vivo. J Control Release. 2014;192:192–201. doi:10.1016/j.jconrel.2014.06.037
   PubMed Web of Science ®Google Scholar
• Qin Y, Chen W, Jiang G, et al. Interfering MSN-NONO complex-activated CREB signaling serves as a therapeutic strategy for triple-negative breast cancer. Sci Adv. 2020;6(8):eaaw9960. doi:10.1126/sciadv.aaw9960
   PubMedGoogle Scholar
• Paris JL, Cabanas MV, Manzano M, Vallet-Regi M. Polymer-grafted mesoporous silica nanoparticles as ultrasound-responsive drug carriers. ACS Nano. 2015;9(11):11023–11033. doi:10.1021/acsnano.5b04378
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhao Y, Teng S, et al. Folic acid receptor-targeted human serum albumin nanoparticle formulation of cabazitaxel for tumor therapy. Int J Nanomedicine. 2019;14:135–148. doi:10.2147/IJN.S181296
   PubMedGoogle Scholar
• Gao F, Zhang J, Fu C, et al. iRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability. Int J Nanomedicine. 2017;12:4147–4162. doi:10.2147/IJN.S134148
   PubMed Web of Science ®Google Scholar
• Gregory JV, Kadiyala P, Doherty R, et al. Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy. Nat Commun. 2020;11(1):5687. doi:10.1038/s41467-020-19225-7
   PubMed Web of Science ®Google Scholar